Viromed Medical AG Halts Acquisition Plans, Shifts Focus to Strategic Innovation

Viromed Medical AG has decided to terminate its plans to acquire ActivCell Group AG. The company had initially intended to purchase all shares of the Swiss firm, valuing the transaction in the mid-single-digit million euro range. The acquisition was to be financed through a capital increase, but Viromed determined that the expected value did not align with its goals.

The decision comes as Viromed refocuses on its existing product, ViroCAP, which is currently undergoing the MDR 2a approval process. The company regards ViroCAP as an advanced and innovative device and aims to bring it to a wider market. This shift in strategy suggests a prioritization of internal development over external acquisitions.

Viromed Medical AG remains committed to enhancing its market presence through strategic innovation rather than through acquisitions that do not meet their value expectations.